The key efficacy endpoint was change from baseline MADRS rating. This small-time period study found that, compared to intranasal placebo plus oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant appreciably improved depressive indications soon after four weeks by a necessarily mean difference of 4 points within the